Tularik

Early pioneer in discovery and development of therapeutics acting through regulation of gene expression

Tularik was focused on drug discovery related to cell signaling and the control of gene expression. Tularik completed its IPO in X and was acquired by Amgen in 2004.

Status

IPO in 1999; Acquired by Amgen in 2004

Year of Investment

1991

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Bay Area, California

Frazier Team